1) The document discusses the increasing number of online touchpoints with customers as health professionals and patients spend more time online. It provides statistics on internet usage and its influence on treatment decisions.
2) It addresses how pharmaceutical companies can connect with customers online given new regulations and guidelines from bodies like the FDA and ABPI.
3) It examines the challenge of managing all the digital assets and activity, both within companies and outside their control, referring to this as "taming the digital sprawl".